Matthew K. Fust has served on our board of directors since February 2018. He is currently a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 through its acquisition by Amgen Inc. in October 2013. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a genetics company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002.

Mr. Fust serves on the board of directors of Atara Biotherapeutics, Inc. and Ultragenyx Pharmaceuticals, Inc., both publicly-traded biopharmaceutical companies. Mr. Fust previously served on the board of directors of both Sunesis Pharmaceuticals, Inc. from May 2005 until May 2017, and MacroGenics, Inc. from March 2014 until May 2020.

Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business.